Please login to the form below

Not currently logged in
Email:
Password:

Tykerb

This page shows the latest Tykerb news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Roche's Kadcyla as "unaffordable"

NICE rejects Roche's Kadcyla as

Clinical data suggests Roche's drug could extend life by up to six months compared with the combination of Xeloda (capecitabine) - also sold by Roche - and GlaxoSmithKline's Tykerb (lapatinib).

Latest news

  • GSK's Tyverb cleared for use alongside Herceptin GSK's Tyverb cleared for use alongside Herceptin

    Last year, GSK withdrew its application for use of the combination in patients who had previously been treated with Roche's drug in the US (where lapatinib is sold as Tykerb) ... GSK had high hopes for Tykerb when it was first launched in 2007 as an oral

  • Roche loses Herceptin patents in India Roche loses Herceptin patents in India

    The Herceptin ruling comes shortly after India revoked a patent granted to GlaxoSmithKline for breast cancer drug Tykerb (lapatinib) under controversial legislation which does not allow patents for incremental innovations, such

  • GSK loses patent on Tykerb in India GSK loses patent on Tykerb in India

    GSK loses patent on Tykerb in India. Cuts period of exclusivity by two years. ... low-cost competition to Tykerb (lapatinib), which had worldwide sales of $160m in the first half of this year.

  • GSK’s Tyverb/ Tykerb disappoints in gastric cancer trial GSK’s Tyverb/ Tykerb disappoints in gastric cancer trial

    GSK’ s Tyverb/ Tykerb disappoints in gastric cancer trial. Fails to improve overall survival in proposed new indication. ... The difference in median overall survival between the two arms was just 1.7 months in favour of patients on Tyverb/ Tykerb

  • Roche's Herceptin follow-up cleared in US Roche's Herceptin follow-up cleared in US

    The agency fast-tracked approval of Kadcyla on the back of data from the 991-patient EMILIA trial, which compared Kadcyla to GlaxoSmithKline's HER2-targetting drug Tykerb (lapatinib) used alongside ... Data from the study showed that overall survival (OS)

More from news
Approximately 2 fully matching, plus 45 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics